Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Finance > Novo Nordisk to take legal action against Hims & Hers for Wegovy compounding

Novo Nordisk to take legal action against Hims & Hers for Wegovy compounding

Published by Global Banking & Finance Review®

Posted on February 5, 2026

1 min read

Last updated: February 5, 2026

Novo Nordisk to take legal action against Hims & Hers for Wegovy compounding - Finance news and analysis from Global Banking & Finance Review

Tags:innovation healthcare insurance financial services

Quick Summary

Novo Nordisk is taking legal action against Hims & Hers for offering compounded Wegovy, citing risks to patient safety and intellectual property concerns.

Novo Nordisk Initiates Legal Action Against Hims & Hers Over Wegovy

Legal Actions and Patient Safety Concerns

COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk said on Thursday it would take legal action against Hims & Hers after the online telehealth company said it will begin offering compounded copies of the Danish group's Wegovy pill at an introductory price of $49 per month.

Novo Nordisk's Statement

"The action by Hims & Hers is illegal mass compounding that poses a significant risk to patient safety," the Danish drugmaker said in a statement.

Compounding Risks and Regulations

"Novo Nordisk will take legal and regulatory action to protect patients, our intellectual property and the integrity of the U.S. gold-standard drug approval framework," it added.

Novo Nordisk said it was the only company that manufactured an FDA-approved Wegovy pill formulated with SNAC technology, which facilitates semaglutide absorption when administered orally.

(Reporting by Louise Rasmussen, editing by Anna Ringstrom)

Key Takeaways

•Novo Nordisk is suing Hims & Hers for compounding Wegovy.
•The company claims this poses a risk to patient safety.
•Wegovy is FDA-approved and manufactured by Novo Nordisk.
•Hims & Hers plans to offer compounded Wegovy at $49/month.
•Novo Nordisk aims to protect its intellectual property.

Frequently Asked Questions about Novo Nordisk to take legal action against Hims & Hers for Wegovy compounding

1What is Wegovy?

Wegovy is a prescription medication developed by Novo Nordisk for weight management. It contains semaglutide, which helps regulate appetite and caloric intake.

2What is mass compounding?

Mass compounding refers to the large-scale preparation of compounded medications, which are customized formulations made by combining different ingredients, often without regulatory oversight.

3What is intellectual property protection?

Intellectual property protection involves legal measures to safeguard creations of the mind, such as inventions, designs, and brand names, preventing unauthorized use by others.

Legal Actions and Patient Safety Concerns

Novo Nordisk's Statement

"The action by Hims & Hers is illegal mass compounding that poses a significant risk to patient safety," the Danish drugmaker said in a statement.

Compounding Risks and Regulations

"Novo Nordisk will take legal and regulatory action to protect patients, our intellectual property and the integrity of the U.S. gold-standard drug approval framework," it added.

Novo Nordisk said it was the only company that manufactured an FDA-approved Wegovy pill formulated with SNAC technology, which facilitates semaglutide absorption when administered orally.

(Reporting by Louise Rasmussen, editing by Anna Ringstrom)

Frequently Asked Questions

1What is Wegovy?

Wegovy is a prescription medication developed by Novo Nordisk for weight management. It contains semaglutide, which helps regulate appetite and caloric intake.

2What is mass compounding?

Mass compounding refers to the large-scale preparation of compounded medications, which are customized formulations made by combining different ingredients, often without regulatory oversight.

3What is intellectual property protection?

Intellectual property protection involves legal measures to safeguard creations of the mind, such as inventions, designs, and brand names, preventing unauthorized use by others.